Renaissance Technologies LLC Raises Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Renaissance Technologies LLC grew its stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 248.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 37,000 shares of the company’s stock after buying an additional 26,383 shares during the quarter. Renaissance Technologies LLC owned 0.12% of Eliem Therapeutics worth $263,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in ELYM. Bank of New York Mellon Corp acquired a new stake in Eliem Therapeutics in the second quarter valued at approximately $134,000. Dimensional Fund Advisors LP purchased a new stake in shares of Eliem Therapeutics in the 2nd quarter valued at approximately $89,000. Finally, Rhumbline Advisers acquired a new stake in shares of Eliem Therapeutics in the 2nd quarter valued at $59,000. 69.76% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eliem Therapeutics

In other news, EVP Valerie Morisset sold 42,377 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $7.01, for a total transaction of $297,062.77. Following the completion of the sale, the executive vice president now owns 252,306 shares in the company, valued at approximately $1,768,665.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 175,981 shares of company stock worth $1,317,125 over the last three months. Insiders own 4.70% of the company’s stock.

Eliem Therapeutics Trading Up 5.4 %

Eliem Therapeutics stock opened at $5.42 on Friday. The stock has a market cap of $161.26 million, a P/E ratio of -10.23 and a beta of -0.39. The company has a fifty day simple moving average of $6.49 and a 200-day simple moving average of $6.68. Eliem Therapeutics, Inc. has a 12-month low of $2.35 and a 12-month high of $11.55.

Eliem Therapeutics (NASDAQ:ELYM) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($1.81) earnings per share (EPS) for the quarter.

Eliem Therapeutics Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.